Recombinant Mouse T-lymphocyte activation antigen CD80 (Cd80)

What is the molecular structure of mouse CD80 and how does it differ from human CD80?

Mouse CD80 is a ~60 kDa single-pass type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily (IgSF). Its structure includes an extracellular region with an IgV-like domain followed by an IgC-like domain, a transmembrane region, and a cytoplasmic tail . Recombinant mouse CD80 protein typically encompasses amino acids 38-246, representing the functional extracellular domain . While human and mouse CD80 share significant structural homology, species-specific differences exist in amino acid sequence and glycosylation patterns that can affect binding affinities to their respective ligands, which should be considered when designing cross-species experiments.

What are the primary cellular expression patterns of CD80 in the mouse immune system?

CD80 is variably expressed on multiple immune cell types in mice, primarily on activated B cells, activated CD4+ and CD8+ T cells, macrophages, and dendritic cells . Expression is typically low or absent on resting cells and is upregulated following activation. When designing experiments, researchers should account for this differential expression pattern by either using appropriate stimulation protocols to induce CD80 expression or selecting specific timepoints post-activation for analysis. Flow cytometry with appropriate controls is the recommended method for quantifying CD80 expression across different immune cell populations.

What signaling pathways are activated by CD80 engagement with its receptors?

CD80 engagement with CD28 on T cells activates several key signaling pathways. This interaction triggers the PI3K/Akt signaling pathway, which stimulates glucose metabolism and ATP synthesis in T cells . Additionally, CD80-CD28 binding activates NF-kappa-B and MAPK pathways, leading to cytokine production . These pathways collectively enhance T cell activation, proliferation, and survival. In contrast, CD80 binding to CTLA-4 (CD152) generates inhibitory signals for T cell responses, demonstrating the dual regulatory role of CD80 . Experimental designs investigating CD80 function should consider both stimulatory and inhibitory outcomes depending on the receptor context.

How should recombinant mouse CD80 be reconstituted and stored to maintain optimal activity?

Recombinant mouse CD80 protein should be reconstituted in sterile, buffer-appropriate conditions according to the manufacturer's specifications. Typically, lyophilized protein should be reconstituted in sterile water or phosphate-buffered saline (PBS) to a concentration of 0.1-1.0 mg/mL. For long-term storage, aliquot the reconstituted protein to avoid repeated freeze-thaw cycles and store at -80°C. Working aliquots can be stored at 4°C for up to one week. Prior to experimental use, centrifuge the protein solution briefly to remove any precipitates. Protein activity should be verified periodically using functional assays such as T cell stimulation or binding assays to ensure the protein maintains its biological activity.

What experimental approaches can effectively measure CD80-CD28 interactions in vitro?

Several methodological approaches can be employed to assess CD80-CD28 interactions:

• Co-immunoprecipitation: Using anti-CD80 or anti-CD28 antibodies to pull down protein complexes, followed by Western blot analysis.

• Surface Plasmon Resonance (SPR): For quantitative measurement of binding kinetics and affinity between recombinant CD80 and CD28 proteins.

• ELISA-based binding assays: Using immobilized CD80 or CD28 to detect interaction with the corresponding partner.

• Functional T cell assays: Measuring T cell proliferation, cytokine production, or activation markers after stimulation with anti-CD3 antibodies in the presence or absence of recombinant CD80.

• Flow cytometry-based binding assays: Using fluorescently labeled CD80 to detect binding to CD28-expressing cells.

When conducting these experiments, appropriate controls should include blocking antibodies against CD80 or CD28, isotype controls, and comparison with known CD80 ligands.

How can researchers effectively validate the functionality of recombinant mouse CD80 protein?

Validating recombinant mouse CD80 functionality requires multiple approaches:

How does CD80 acquisition by T cells impact experimental interpretation and what methodologies can distinguish acquired versus endogenously expressed CD80?

CD80 acquisition by T cells represents a critical consideration in experimental design and data interpretation. Research has demonstrated that CD4+ T cells can acquire CD80 from antigen-presenting cells (APCs) at early stages of activation (24 hours), which is not due to endogenous upregulation but rather intercellular transfer . This phenomenon has significant implications for interpreting CD80 positivity on T cells in experimental settings.

To distinguish between acquired and endogenously expressed CD80:

• Cycloheximide treatment: Treating T cells with protein synthesis inhibitors like cycloheximide before co-culture with APCs can confirm CD80 acquisition rather than de novo synthesis .

• mRNA analysis: RT-PCR for CD80 mRNA in T cells showing CD80 protein expression can determine whether the protein is endogenously produced .

• Time-course experiments: CD80 acquisition occurs rapidly (within 24 hours) while endogenous expression typically requires longer activation periods.

• Fluorescent labeling: Pre-labeling APC-expressed CD80 with fluorescent tags can track transfer to T cells.

Importantly, T cells that acquire CD80 from APCs can themselves stimulate other T cells, potentially amplifying immune responses in experimental systems . This mechanism should be considered when interpreting T cell activation data in co-culture systems.

What role does CD80 play in multiple sclerosis models, and how should experiments be designed to investigate this connection?

Research indicates important connections between CD80 expression and multiple sclerosis (MS) pathophysiology. Studies have shown reduced CD80 expression in Epstein-Barr virus (EBV)-infected B cells (LCLs) from MS patients compared to healthy donors, with this reduction being more pronounced in females . The relationship between CD40 and CD80 expression appears particularly relevant, as there is interdependence between CD40 and CD80 protein levels in MS-derived LCLs but not in healthy donor cells .

When designing experiments to investigate CD80's role in MS models:

• Sex-stratified analysis: Given the more pronounced CD80 expression differences in females with MS, experiments should be stratified by sex .

• EBV variant consideration: The type of EBV used in experimental systems affects CD80 expression, with endogenous EBV variants showing different effects than laboratory strains like B95.8 .

• Genetic background assessment: Host genetic variants may interact with CD80 expression patterns, necessitating genotyping for MS-associated SNPs in experimental subjects .

• Combined CD40/CD80 analysis: The interdependence between CD40 and CD80 suggests both should be analyzed simultaneously in MS research contexts .

• Flow cytometry protocols: For accurate quantification of CD80 expression differences, standardized flow cytometry protocols with appropriate isotype controls and consistent gating strategies are essential.

How can researchers implement experimental controls to distinguish between the stimulatory and inhibitory functions of CD80 in T cell activation studies?

CD80 exhibits dual functionality through its interactions with both CD28 (stimulatory) and CTLA-4 (inhibitory) on T cells . Designing experiments that can distinguish between these opposing functions requires careful control implementation:

• Receptor-blocking experiments: Utilize specific blocking antibodies or fusion proteins (soluble CTLA-4, CD28, and CD80) to selectively prevent interaction with either CD28 or CTLA-4 .

• Temporal analysis: Since CD28 is constitutively expressed while CTLA-4 is upregulated after activation, time-course experiments can help distinguish early (predominantly CD28-mediated) versus late (mixed CD28/CTLA-4-mediated) effects.

• Genetic approaches: Use CD28-knockout or CTLA-4-knockout T cells to isolate effects mediated by each receptor.

• Dose-response relationships: CD80 typically binds CTLA-4 with higher affinity than CD28, so titrating CD80 concentrations can help differentiate between predominantly stimulatory (lower concentrations) versus inhibitory (higher concentrations) effects.

• Functional readouts: Include multiple readouts that differentially reflect stimulatory versus inhibitory signaling, such as proliferation, IL-2 production (stimulatory), and markers of T cell exhaustion (inhibitory).

What are the critical quality control parameters for recombinant mouse CD80 protein used in experimental systems?

When using recombinant mouse CD80 protein in research, several quality control parameters should be routinely assessed:

• Purity assessment: Recombinant mouse CD80 should demonstrate ≥90% purity by SDS-PAGE analysis . Contaminants can affect experimental outcomes, particularly in sensitive assays like T cell activation studies.

• Endotoxin testing: Endotoxin levels should be <0.1 EU/μg protein, as endotoxin contamination can independently activate immune cells and confound results.

• Protein conformation: CD80's functional activity depends on proper protein folding; techniques like circular dichroism spectroscopy can verify secondary structure integrity.

• Glycosylation analysis: As a glycoprotein, CD80's functionality may be affected by glycosylation patterns, which can vary between expression systems. Expression in mammalian systems like HEK293 cells provides more physiologically relevant glycosylation .

• Functional validation: Biological activity should be confirmed using binding assays with recombinant CD28 and CTLA-4, as well as T cell co-stimulation assays measuring proliferation or cytokine production.

• Batch consistency: Experimental consistency requires using the same protein batch throughout a study or validating batch-to-batch equivalency through standardized functional assays.

How can researchers optimize flow cytometry protocols for accurate detection and quantification of CD80 in different mouse immune cell populations?

Flow cytometry optimization for CD80 detection requires addressing several technical considerations:

• Antibody selection: Choose anti-CD80 antibody clones with validated specificity for mouse CD80. The 2D10.4 clone has been well-characterized for specificity .

• Fluorochrome pairing: Select fluorochromes based on instrument configuration and other markers in the panel. PE-conjugated anti-CD80 antibodies offer good sensitivity for detecting varying CD80 expression levels .

• Titration curves: Perform antibody titration to determine optimal concentration that maximizes signal-to-noise ratio.

• Blocking strategy: Include Fc receptor blocking to prevent non-specific binding, particularly important when analyzing macrophages and dendritic cells.

• Controls implementation:

  • Isotype controls at the same concentration as the test antibody

  • Fluorescence-minus-one (FMO) controls for accurate gating

  • Positive controls (LPS-stimulated B cells) and negative controls (resting T cells)

• Viability discrimination: Include viability dyes to exclude dead cells, which can bind antibodies non-specifically.

• Standardization: Use calibration beads to standardize fluorescence intensity across experiments and instruments.

• Sample processing considerations: Minimize time between sample collection and staining, and maintain consistent processing protocols to reduce variability in CD80 detection.

What strategies can address common challenges in studying CD80 acquisition by T cells from antigen-presenting cells?

Investigating CD80 acquisition by T cells presents several methodological challenges that can be addressed through the following strategies:

• Distinguishing acquisition from upregulation:

  • Use RNA analysis (RT-PCR) to confirm absence of CD80 mRNA in T cells that display CD80 protein

  • Employ protein synthesis inhibitors like cycloheximide during co-culture experiments

  • Design time-course experiments capturing very early timepoints (CD80 acquisition occurs within 24 hours)

• Quantifying acquisition efficiency:

  • Standardize APC:T cell ratios in co-culture experiments

  • Utilize FACS-sorted populations to ensure cell purity

  • Implement cell tracking dyes to distinguish populations during analysis

• Visualizing the acquisition process:

  • Use confocal microscopy with fluorescently labeled CD80 to directly observe transfer

  • Implement live-cell imaging to capture the dynamics of acquisition

• Controlling for confounding factors:

  • Include transwell experiments to confirm cell-cell contact requirement

  • Use blocking antibodies (anti-CD28, anti-CD80) to assess receptor dependency

  • Compare results across different types of APCs with varying CD80 expression levels

• Functional verification:

  • Test whether T cells that have acquired CD80 can stimulate other T cells

  • Measure functional outcomes like cytokine production or proliferation

By implementing these methodological approaches, researchers can more accurately characterize the biological significance of CD80 acquisition by T cells and its potential immunoregulatory implications.

What are emerging methodologies for studying CD80's role in T cell-mediated immune responses?

Recent technological advances offer new opportunities for investigating CD80 biology:

• Single-cell RNA sequencing: Enables correlation of CD80 expression with comprehensive transcriptional profiles at individual cell resolution, revealing heterogeneity in CD80-expressing populations.

• CRISPR-Cas9 genetic modifications: Allows precise editing of CD80 gene or its regulatory elements to study structure-function relationships and expression control mechanisms.

• Sophisticated imaging techniques: Super-resolution microscopy and intravital imaging provide insights into CD80 clustering, interaction dynamics, and in vivo behavior during immune responses.

• Biosensors and reporter systems: Development of CD80-interaction biosensors can enable real-time monitoring of CD80-CD28/CTLA-4 binding events in living cells.

• Organoid and 3D culture systems: These more physiologically relevant models can better recapitulate CD80's role in tissue-specific immune environments compared to traditional 2D cultures.

These methodologies will help address fundamental questions about spatiotemporal dynamics of CD80 expression and its functional consequences in complex immune responses.